利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

699 records (took 0.033 seconds)

    A PEPTIDE MIXTURE
    41.
    发明公开
    A PEPTIDE MIXTURE 有权
    PEPTIDMISCHUNG

    公开(公告)号：EP3079715A2

    公开(公告)日：2016-10-19

    申请号：EP14828148.8

    申请日：2014-12-09

    Applicant: TARGOVAX ASA

    Inventor： ERIKSEN, Jon Amund

    IPC: A61K39/00 ,  C07K14/47 ,  A61P35/00 ,  C07K14/82

    CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/82 ,  C12Q2600/156 ,  G01N33/483 ,  G01N33/505 ,  G01N2333/47

    Abstract: There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the RAS protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the RAS protein. Each of said regions of the first and second peptides independently has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. Each of the first and the second peptides has a point mutation at the amino acid corresponding to said position 13. The point mutation of the first peptide is different from the point mutation of the second peptide.

    Abstract translation: 公开了适于引发免疫应答的肽混合物。 它包含第一和第二肽，每个肽对应于RAS蛋白的片段。 第一和第二肽中的每一个包含至少8个氨基酸的区域，其包括RAS蛋白质的第13位。 第一和第二肽的每个所述区域独立地具有至少6个氨基酸残基，而不是在所述位置13，其与RAS蛋白质的相应区域相同。 第一和第二肽中的每一个在对应于所述位置13的氨基酸处具有点突变。第一肽的点突变不同于第二肽的点突变。

    BLOOD BIOMARKERS THAT PREDICT PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION
    42.
    发明公开
    BLOOD BIOMARKERS THAT PREDICT PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSION 有权
    BLUTBIOMARKER于预测持续性认知功能障碍后脑SHAKE

    公开(公告)号：EP2971285A4

    公开(公告)日：2016-09-28

    申请号：EP14768466

    申请日：2014-03-14

    Applicant: UNIV PENNSYLVANIA

    Inventor： SIMAN ROBERT

    IPC: C40B30/04 ,  G01N33/00 ,  G01N33/566 ,  G01N33/68

    CPC classification number: G01N33/566 ,  G01N33/6896 ,  G01N2333/47 ,  G01N2333/4703 ,  G01N2800/28 ,  G01N2800/2871 ,  G01N2800/50 ,  G01N2800/52

    Abstract: The invention relates to methods for providing prognosis, diagnosis, monitoring and treatment of a mild traumatic brain injury (mTBI) in a subject, including a sports-related concussion. The invention further relates to assessing the severity of brain damage resulting from mTBI in a subject, including in a subject who has not undergone a CT scan following the injury. For example, the methods of the invention can be used to determine the suitability for someone who has suffered a sports-related injury to return to play that sport. This invention also relates to methods of predicting risk for developing brain damage and long-term dysfunction in a subject having suffered mTBI.

    Abstract translation: 本发明涉及一种方法用于在受试者提供预后，诊断，监测和治疗轻度创伤性脑损伤（MTBI），其中包括与体育有关的脑震荡。 本发明还涉及到assesing脑损伤的从MTBI导致的严重性，主题，包括谁没有经过CT扫描继损伤的受试者。 例如，本发明的方法可用于确定矿的人谁遭受了运动相关的损伤回到赛场，体育的适用性。 因此，本发明涉及一种用于预测在开发一个主题的脑损伤和长期功能障碍遭受MTBI风险的方法。

    THYROGLOBULIN QUANTITATION BY MASS SPECTROSCOPY
    48.
    发明公开
    THYROGLOBULIN QUANTITATION BY MASS SPECTROSCOPY 审中-公开
    胰蛋白酶定量法的质谱分析

    公开(公告)号：EP2898088A4

    公开(公告)日：2016-04-20

    申请号：EP13839646

    申请日：2013-09-19

    Applicant: QUEST DIAGNOSTICS INVEST INC

    Inventor： ZHANG YANNI ,  CLARKE NIGEL J ,  REITZ RICHARD E

    IPC: C12Q1/37 ,  G01N33/68

    CPC classification number: G01N33/6848 ,  C12Q1/37 ,  G01N33/6893 ,  G01N33/78 ,  G01N2333/47 ,  G01N2496/00 ,  G01N2560/00 ,  G01N2800/046 ,  G01N2800/7028

    Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.

    Abstract translation: 提供了使用各种纯化步骤随后进行质谱法测定样品中甲状腺球蛋白量的方法。 所述方法通常涉及纯化测试样品中的甲状腺球蛋白，消化甲状腺球蛋白以形成肽T129，纯化肽T129，电离肽T129，检测产生的肽T129离子的量，并将肽T129离子的量与原始存在的甲状腺球蛋白的量相关联 在样品中。

    PROCEDE DE MESURE DE LA CONCENTRATION PLASMATIQUE D'UN ANALYTE DIRECTEMENT SUR UN ECHANTILLON DE SANG TOTAL
    49.
    发明公开
    PROCEDE DE MESURE DE LA CONCENTRATION PLASMATIQUE D'UN ANALYTE DIRECTEMENT SUR UN ECHANTILLON DE SANG TOTAL 有权
    VERFAHREN ZUR MESSUNG DER PLASMAKONZENTRATION EINES ANALYTEN DIREKT AUF EINER VOLLBLUTPROBE

    公开(公告)号：EP2997381A1

    公开(公告)日：2016-03-23

    申请号：EP14731684.8

    申请日：2014-05-12

    Applicant: Biomérieux

    Inventor： CHEUCLE, Sylvie ,  MARILLET, Laure ,  THOLLET, Aurélie

    IPC: G01N33/68

    CPC classification number: G01N33/543 ,  G01N33/6887 ,  G01N2333/47 ,  G01N2333/4706 ,  G01N2333/75 ,  G06F19/24

    Abstract: A method for measuring an amount of analyte in a whole blood sample comprises: - measuring the haematocrit level of the whole blood sample; - measuring an amount of analyte directly in the whole blood sample; and - calculating an amount of analyte corrected according to the relationship: D
    p = P
    a (D
    ST , D
    H ) where D
    p is the corrected amount of analyte, D
    ST is the measured amount of analyte, D
    H is the measured haematocrit level, and P
    a is a non-constant polynomial having a degree greater than or equal to 1, the indeterminate values of which are the measured amount of analyte D
    ST and the measured haematocrit level D
    H , and the polynomial coefficients of which are dependent on the analyte.

    Abstract translation: 一种测定全血样品中的分析物量的方法，包括：测定全血样品的血细胞比容水平; 在全血样品中直接测量分析物量; 并且根据关系式计算校正的分析物量：DP = Pa（DST，DH）其中Dp是校正的分析物量，DST是测量的分析物量，DH是测量的血细胞比容水平，Pa是非常数多项式 大于或等于1，具有测量的分析物量，DST和测量的血细胞比容水平DH作为不确定值，并且其多项式系数取决于分析物。

Patent Agency Ranking